The study examined adverse events (AE) in 182 children and adolescents receiving anti-tuberculosis treatment. AE were detected in 103 (56.6%) patients. The most common were toxic reactions (79.6%), less common were toxic-allergic (12.6%) and allergic (7.8%) reactions. In adolescents, allergic (11.1% vs 6.0%) and toxic-allergic (19.4% vs 9.1%) reactions were significantly more common than in children (P<0.05). In adolescents, allergic (11.1% vs 6.0%) and toxic-allergic (19.4% vs 9.1%) reactions were significantly more common than in children (P<0.05). In patients with drug-resistant TB, AEs were observed 1.7 times more often than in patients with sensitive TB (81.6% vs 47.4%, P<0.05).

Tuberculosis, adolescents, anti-tuberculosis therapy

Aleksandrova E.N., Morozova T.I., Salina T.Yu. Tuberculosis situation among the pediatric population of Saratov Region (2015-2019). Tuberculosis and Lung Diseases. 2021;99(12):33-37. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-12-33-37

Bates D. W., Miller E. B., Cullen D. J. Patient Risk Factors for Adverse Drug Events in Hospitalized Patients // Arch Intern Med. – 1999. – Vol. 159. – P. 2553-2560. [ONLINE] Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485185 [Accessed 10 March 2018].

Belyaeva E. N., Chernokhaeva I. V., Starshinova A. A., Pavlova M. V., Sapozhnikova N. V., Archakova L. I. Spectrum of adverse reactions in combination therapy of tuberculosis of the respiratory organs with multiple and extensive drug resistance of the pathogen with the inclusion of the drug perchlozone. // Tuberculosis and lung diseases. - 2015. - V. 93, No. 7. - P. 24-30.

Borisov S.E. ADverse side effects of tuberculosis etiotropic treatment regimens containing the new anti-tuberculosis drug of SQ109. Tuberculosis and Lung Diseases. 2018;96(7):65-66. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-7-65-66

Chen R., Wang J., Tang S. W., Lyu X. Z., Zhang Y., Wu S. S., Xia Y. Y., Zhan S. Y. Study on polymorphisms of genes with susceptibility to drug-induced liver injury in a cohort receiving anti-tuberculosis treatment // Zhonghua Liu Xing Bing Xue Za Zhi. – 2016 Jul;37(7): P. 925-929.

Fang Y., Xiao H., Tang S., Liang L., Sha W., Fang Y. Clinical features and treatment of drug fever caused by anti-tuberculosis drugs // Clin Respir J. – 2016 Jul;10(4): P. 449-454.

Global Tuberculosis Report 2020. WHO/CDS/TB/2020. – Geneva, World Health Organization, 2020. – P. 232.

Gubkinа M.F., Khokhlovа Yu.Yu., Petrаkovа I.Yu., Yukhimenko N.V. Tolerability of individual chemotherapy regimens in children suffering from respiratory tuberculosis and exposed to multiple and extensive drug resistant tuberculosis. Tuberculosis and Lung Diseases. 2021;99(3):29-33. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-3-29-33

Gubkina M. F., Khokhlova Yu. Yu., Yukhimenko N. V., Petrakova I. Yu. Frequency and nature of undesirable side effects in the treatment of tuberculosis of the respiratory organs in children from foci with multiple and extensive drug resistance of the pathogen // V Congress of the National Association of Phthisiologists. - St. Petersburg, 2016. - P. 55-56.

Gupta A., Srivastava V. K., Khanna V. N., Rizvi I. Paradoxical reaction to antitubercular therapy in miliary tuberculosis // BMJ Case Rep. – 2012 Sep 3;2012. – P. 2012-6142.

Komissarova O.G., Аbdullaev R.Yu., Aleshina S.V. Frequency and characteristics of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with diabetes myelitis. Tuberculosis and Lung Diseases. 2020;98(2):10-14. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-2-10-14

Nikiforenko N.A., Lozovskaya M.E., Novik G.А., Derevyanko А.V., Kochmarev N.V. The Role of Risk Factors in the Development of Tuberculosis in Children Exposed to Rifampicin Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2021;99(7):18-25. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-7-18-25

Romanova M. A., Mordyk A. V. Frequency and types of adverse effects of chemotherapy in children // V Congress of the National Association of Phthisiologists. - St. Petersburg, 2016. - P. 201-202.

Schegertsov D.Yu., Filinyuk O.V., Buynova L.N., Zemlyanaya N.A., Kabanets N.N., Alliluev A.S. Adverse events during treatment of patients suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases. 2018;96(3):35-43. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-3-35-43

Tashpulatova F.K. et al. Frequency and nature of drug-induced complications from chemotherapy drugs in patients with drug-resistant pulmonary tuberculosis // Medicine: today's challenges: Proc. III Int. sci. conf. (Moscow, January 2016). - Moscow: Buki-Vedi, 2016. - P. 50-53. - URL: https://moluch.ru/conf/med/archive/193/9467/

Toktogonova A.A. Frequency and characteristics of adverse reactions to second line anti-tuberculosis drugs in those ill with multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases. 2017;95(10):63-67. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-10-63-67

Voznenko A. A., Novikova T. I. Side effects of anti-tuberculosis drugs in the treatment of tuberculosis // Medical Bulletin of the North Caucasus. - 2007. - No. 3. - P. 32-33.

Wolf S. B. Undesirable side effects of tuberculosis chemotherapy // Journal of Grodno State Medical University. - 2016. - No. 3. - P. 141-146.

Wolf S. B. Adverse effects of polychemotherapy of tuberculosis // Journal of GrSMU. - 2006. - No. 1. - P. 61-63.